Table 2.
Patient characteristics.
| Characteristics of the patients at baseline | mean / n | sd / % |
|---|---|---|
| Demographics | ||
| Male (n) | 3 | 25,0% |
| Age (y) | 58.6 | 14.0 |
| Disease duration (y) | 10.2 | 6.5 |
| MG-ADL total score | 7.5 | 2.6 |
| QMG Total score | 12.8 | 4.1 |
| AChR Antibody levels (nmol/L) | 52.7 | 55.1 |
| Thymectomy (n) | 7 | 58.3% |
| Thymoma (n) | 3 | 25.0% |
| MG Therapy | ||
| Any Steroid (n) | 10 | 83.3% |
| Any Steroid (mg) | 18.8 | 10.5 |
| Any NSIT (n) | 5 | 41.7% |
| Any AChEI (n) | 8 | 66.7% |
| IVIg /Plex (n) | 7 | 58.3% |
| Steroid+NSIT (n) | 4 | 33.3% |
| AChEI only (n) | 1 | 8.3% |
| Type of patients | ||
| pO (n) | 4 | 33.3% |
| pB (n) | 4 | 33.3% |
| pG (n) | 4 | 33,3% |
n, frequency; sd, standard deviation; y, yars; NSIT, Non-steroidal immunosuppressants treatments; AChEI, acetylcholinesterase inhibitor; IVIg, immunoglobulins in vein; Plex, plasmapheresis; pO, predominantly Ocular; pB, predominantly Bulbars; pG, predominantly Generalized.